BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23497487)

  • 1. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer.
    Strati A; Kasimir-Bauer S; Markou A; Parisi C; Lianidou ES
    Breast Cancer Res; 2013 Mar; 15(2):R20. PubMed ID: 23497487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
    Tewes M; Aktas B; Welt A; Mueller S; Hauch S; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res Treat; 2009 Jun; 115(3):581-90. PubMed ID: 18679793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of circulating tumor cells in breast cancer patients using multiplex reverse transcription-polymerase chain reaction and specific primers for MGB, PTHRP and KRT19 correlation with clinicopathological features.
    Skondra M; Gkioka E; Kostakis ID; Pissimissis N; Lembessis P; Pectasides D; Koutsilieris M
    Anticancer Res; 2014 Nov; 34(11):6691-9. PubMed ID: 25368276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes.
    Schröder CP; Ruiters MHJ; de Jong S; Tiebosch ATMG; Wesseling J; Veenstra R; de Vries J; Hoekstra HJ; de Leij LFMH; de Vries EGE
    Int J Cancer; 2003 Sep; 106(4):611-618. PubMed ID: 12845661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
    Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
    Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
    Kasimir-Bauer S; Hoffmann O; Wallwiener D; Kimmig R; Fehm T
    Breast Cancer Res; 2012 Jan; 14(1):R15. PubMed ID: 22264265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.
    Politaki E; Agelaki S; Apostolaki S; Hatzidaki D; Strati A; Koinis F; Perraki M; Saloustrou G; Stoupis G; Kallergi G; Spiliotaki M; Skaltsi T; Lianidou E; Georgoulias V; Mavroudis D
    Cell Physiol Biochem; 2017; 44(2):594-606. PubMed ID: 29161698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
    Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T;
    Breast Cancer Res; 2012 Aug; 14(4):R118. PubMed ID: 22894854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.
    Obermayr E; Sanchez-Cabo F; Tea MK; Singer CF; Krainer M; Fischer MB; Sehouli J; Reinthaller A; Horvat R; Heinze G; Tong D; Zeillinger R
    BMC Cancer; 2010 Dec; 10():666. PubMed ID: 21129172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.
    Aktas B; Tewes M; Fehm T; Hauch S; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res; 2009; 11(4):R46. PubMed ID: 19589136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.
    Andreopoulou E; Yang LY; Rangel KM; Reuben JM; Hsu L; Krishnamurthy S; Valero V; Fritsche HA; Cristofanilli M
    Int J Cancer; 2012 Apr; 130(7):1590-7. PubMed ID: 21469140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
    Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
    Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
    Yie SM; Luo B; Ye NY; Xie K; Ye SR
    Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
    Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
    Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients.
    Bostick PJ; Chatterjee S; Chi DD; Huynh KT; Giuliano AE; Cote R; Hoon DS
    J Clin Oncol; 1998 Aug; 16(8):2632-40. PubMed ID: 9704713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer.
    Banys M; Krawczyk N; Becker S; Jakubowska J; Staebler A; Wallwiener D; Fehm T; Rothmund R
    Breast Cancer Res Treat; 2012 Feb; 132(1):121-9. PubMed ID: 21562707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating microRNA-based screening tool for breast cancer.
    Frères P; Wenric S; Boukerroucha M; Fasquelle C; Thiry J; Bovy N; Struman I; Geurts P; Collignon J; Schroeder H; Kridelka F; Lifrange E; Jossa V; Bours V; Josse C; Jerusalem G
    Oncotarget; 2016 Feb; 7(5):5416-28. PubMed ID: 26734993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
    Chen Y; Zou TN; Wu ZP; Zhou YC; Gu YL; Liu X; Jin CG; Wang XC
    Int J Biol Markers; 2010; 25(2):59-68. PubMed ID: 20586026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.